[Cardiotoxicity induced by chemotherapy: possibilities of diagnosis]
- PMID: 15575493
[Cardiotoxicity induced by chemotherapy: possibilities of diagnosis]
Abstract
The authors give a brief summary about the process and significance of cardiotoxicity produced by chemotherapy and irradiation used for malignancy. After the introduction, those invasive and noninvasive processes are put into focus and explained in detail, which are applied in the research of the effects of cardiotoxic chemotherapy. The clinical importance of this research is the life prolongation effect of the treatment, which allows the late-appearing toxic cardiomyopathy, resulting in congestive heart failure and increasing mortality. Summarizing the last decade's progress in research, it is evident that even in the planning of chemotherapy, the cardiovascular risks have to be taken into account, because they can greatly influence the cardiac side effect of the treatment.
Similar articles
-
Chemotherapy-induced cardiomyopathy.Heart Fail Rev. 2015 Nov;20(6):721-30. doi: 10.1007/s10741-015-9502-y. Heart Fail Rev. 2015. PMID: 26338137 Review.
-
Reversible Cardiomyopathy After Epirubicin Administration.Int Heart J. 2015;56(4):466-8. doi: 10.1536/ihj.14-416. Epub 2015 Jun 24. Int Heart J. 2015. PMID: 26104177
-
Chemotherapy-induced cardiomyopathy.Expert Rev Cardiovasc Ther. 2011 Feb;9(2):231-43. doi: 10.1586/erc.10.188. Expert Rev Cardiovasc Ther. 2011. PMID: 21506294 Review.
-
The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients.Neurol Neurochir Pol. 2014;48(2):111-5. doi: 10.1016/j.pjnns.2013.12.005. Epub 2014 Jan 23. Neurol Neurochir Pol. 2014. PMID: 24821636
-
Pathophysiology and diagnosis of cancer drug induced cardiomyopathy.Cardiovasc Toxicol. 2007;7(2):61-6. doi: 10.1007/s12012-007-0016-2. Cardiovasc Toxicol. 2007. PMID: 17652805 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical